Community pharmacist-led inhaler choice for improvement of lung function in COPD

Not Applicable

Recruiting

• Conditions: Chronic Obstructive Pulmonary Disease

• Registration Number: JPRN-UMIN000052218
• Lead Sponsor: Satoshi Dote, Department of Pharmacy, Kyoto-Katsura Hospital.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-10-01
• Last Update Posted: 17 October 2023
• Study Completion: 2025-03-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

Stage IV (%FEV1<30%) Dementia Prognosis is predicted within one year Overlap with bronchial asthma Informed consent is not obtained

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change of FEV1 (Forced Expiratory Volume 1 second) from baseline to week 12

Secondary Outcome Measures

Name	Time	Method
Forced Vital Capacity (FVC), Inspiratory Capacity (IC), COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) Dyspnea Scale, EuroQol 5 dimensions (EQ-5D), Safety